AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT05261399Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have...AstraZeneca · CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 6, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04157348Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.AstraZeneca · Eosinophilic Granulomatous VasculitisActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 10, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc. · NMOSDActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 7, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03737643Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib...AstraZeneca · Advanced Ovarian CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 17, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and...AstraZeneca · AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05883644Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)AstraZeneca · Advanced Hepatocellular CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 30, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT00099437Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer...AstraZeneca · Breast CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 27, 2009Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT01874353Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyAstraZeneca · Platinum SensitiveActive, not recruitingAZNLeadMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 19, 2016Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT01933932Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat...AstraZeneca · Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jun 7, 2016Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02453282Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung...AstraZeneca · Non-Small-Cell Lung Carcinoma NSCLCActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 4, 2018Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02516241Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerAstraZeneca · Urothelial CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 27, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02542293Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)AstraZeneca · Non Small Cell Lung Carcinoma NSCLCActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Sep 21, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT03043872Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)AstraZeneca · Small Cell Lung Carcinoma Extensive DiseaseActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 27, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZeneca · CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 18, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05104866A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable...AstraZeneca · Breast CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 24, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05374512A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic...AstraZeneca · Breast CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 25, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04075292Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaAstraZeneca · Untreated Chronic Lymphocytic LeukemiaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 3, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07000136A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHAstraZeneca · Heterozygous Familial HypercholesterolaemiaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 4, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06194825EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With...AstraZeneca · Transthyretin Amyloid CardiomyopathyActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- May 13, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06635447Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsAstraZeneca · Breast CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07000123A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventAstraZeneca · Cardiovascular DiseaseActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 11, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06706817A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment...AstraZeneca · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Primary completion
- Jan 13, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05043090Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCAstraZeneca · Papillary Renal Cell CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT03732820Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerAstraZeneca · Metastatic Castration-resistant Prostate CancerActive, not recruitingAZNLeadMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 30, 2021Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05171816Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZeneca · Metastatic Castration-resistant Prostate CancerActive, not recruitingAZNLeadMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 22, 2024Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.